Document is current
Any future updates will be listed below
-
Authors
Ozdede, Ayse https://orcid.org/0000-0002-6531-8138
Guner, Sabriye https://orcid.org/0000-0002-9582-8374
Ozcifci, Guzin https://orcid.org/0000-0002-4774-9284
Yurttas, Berna https://orcid.org/0000-0002-6096-0340
Toker Dincer, Zeynep https://orcid.org/0000-0002-0762-7725
Atli, Zeynep https://orcid.org/0000-0002-2959-0978
Uygunoğlu, Uğur https://orcid.org/0000-0003-2866-4004
Durmaz, Eser https://orcid.org/0000-0002-1468-0153
Uçar, Didar https://orcid.org/0000-0002-3469-7307
Uğurlu, Serdal https://orcid.org/0000-0002-9561-2282
Saip, Sabahattin https://orcid.org/0000-0002-2802-7227
Tabak, Fehmi https://orcid.org/0000-0001-8632-2825
Hamuryudan, Vedat https://orcid.org/0000-0001-6625-1652
Seyahi, Emire https://orcid.org/0000-0003-4965-2918
- License Information
-
More Information
Article History
Received: 21 February 2022
Accepted: 16 March 2022
First Online: 4 April 2022
Declarations
:
: Ayse Ozdede, Sabriye Guner, Guzin Ozcifci, Berna Yurttas, Zeynep Toker Dincer, Zeynep Atli, Ugur Uygunoglu, Eser Durmaz, Didar Ucar, Sabahattin Saip, and Vedat Hamuryudan declare that they have no conflict of interest. Serdal Ugurlu has received honoraria, consulting or speaker fees from Novartis, Pfizer, Lilly and Celltrion. Fehmi Tabak, has received honoraria, consulting or speaker fees from GSK, MSD, AbbVie and Gilead. Emire Seyahi has received honoraria, consulting or speaker fees from Novartis, Pfizer, AbbVie and Gilead.
Free to read: This content has been made available to all.
